AWK Share Price Performance
€18.10
11.05 (156.74%)
Price €18.10
Share Pricen/a
Avadel Pharmaceuticals plc Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
AWK Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Avadel Pharmaceuticals plc Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.0028
- 94.91%
- -0.11%
- 35.5%
About AWK
- Founded
- 2015
- Employees
- 188
- CEO
- WebsiteView website
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
